A trend to market-driven health care in many parts of the world is focusing increasing attention on getting maximum value from available resources. Laboratories are not exempted. Well-informed clinical input has a potentially valuable role in any laboratory rationalization process. However, a communication difficulty exists in the sense that, although laboratory workers, commercial developers, regulatory bodies, etc., are thoroughly conditioned to using assay coefficient of variation as a general perfor-. mance measure (for excellent reasons), this is not necessarily the most intuitive or informative scale from a clinician's perspective. Here we use routine clinical data from an immunoradiometnc assay of thyrotropin to illustrate, first, a general approach to estimation and prediction of reproducibility, and second, an alternative summary that expresses the discriminatory power of an assay. This latter measure, our experience suggests, is more suited to the way clinicians perceive assays and assay results. The overall aim is improved clinician! laboratory communication.
tively, what is the minimum distinguishable difference in concentration ( Figure 1B) ? The latter quantity, D, has the advantage that it expresses the discriminatory power of an assay directly.1 In fact, D is just an alternative way of sununarizing reproducibility data, a way of facilitating informed discussion between clinicians and laboratory staff.
Here we use data from an immunoradiometric assay (IRMA) of thyrotropin (TSH) to illustrate the calculation of D and ways in which this quantity can be used as a communication aid.
Materials and Methods

Data
From January through September 1991, all clinical specimen and quality-control (QC) specimen results from a TSH IRMA (Serono, Woking, UK) were stored on computer disk. All specimens were assayed in duplicate. Collectively, the assays were performed by three different technicians.
The number of clinical results (1476) is atypically small for a 9-month period because, until as late as mid-August 1991, we had continued to use an in-house TSH radioinimunoassay as a very-low-cost "screening" assay. Specimens assigned to the IRMA represented the full clinical spectrum, but more than half were selected on the basis of suspected thyrotoxicosis.
Ten different QC specimens were used, covering the range -0.1 to ' 
Least Detectable Concentration (LDC)
The smallest concentration statistically distinguishable from zero is a special case of Figure 1B ; by setting Li =0, L2 becomes the LDC. This is well approximated by slight modification of equation 5:
After substituting an estimate of within-or betweenassay variability (equations 2 or 3, respectively), solving equation? for U yields the LDC. By adjusting the values of Z, r, or r in equations 2 or 3, a solution can be Thewithin-assay profile hasbeenadjusted to reflect duplicate measurement. Thesnow Indicatesthe lowerlimitof the reference range (0.4 mlU/L) produced for any specified significance level or degree of replication. An iterative process is required; we have found that Newton's method gives rapid convergence.
Alternatively, a graphical approach can be used. After multiplying through by 100/U, and rearranging, equation 7 reduces to CV = 70.71/Z. This is the "critical" CV for a specified significance level (thus, CVs of 42.9% and 30.3% represent the 5% and 1% significance levels, respectively). Interpolation from an imprecision profile plot (within-assay or between-assay, as appropriate) yields the LDC. Degree of replication is given by the degree of replication associated with the profile. Equation 2 or 3 can be used to adjust profile plots to represent any degree of replication before interpolation. Figure 2(A, B) shows the data and the estimated within-and between-assay variance functions plotted in terms of SD. Estimate of D Figure 3 illustrates between-assay discrimination characteristics, for duplicate and singleton measurement, at the 5% significance level; i.e., at any particular concentration, the value of D found by interpolation is the minimum distinguishable concentration difference, in between-assay mode, with P <0.05. Similar diagrams representing the 1% or any other significance level are easily constructed. The 5% level was chosen on the grounds that a TSH result in this laboratory is invariably augmented by measurements of one or both thyroid hormones; hence, this test has a lower "degree-of-certainty" requirement than might be the case for a single stand-alone test. Most important, the choice reflects the personal perception of a major consumer of the TSH results (one of us, J. G. T., is a consulting thyroid physician).
Results
Estimates of Reproducibility
Assay characteristics at the lower limit of the reference range (0.4 mJU/L) are particularly important in the case of TSH. The minimum distinguishable difference for duplicate measurement (see Figure 3) is 0.09 nilU/L (or ± 0.045 mllJ/L); therefore, we can conclude that at the lower reference point, and for duplicate measurement, the minimum distinguishable range is 0.355-0.445 mIU/L, with P <0.05. Whether or not this is favorable news from a clinician's perspective, it is almost certainly more informative than reporting that between-assay CV is 9.6% at the lower reference point. Figure 3 also allows evaluation of the consequences of a switch from duplicate to singleton measurement. At the lower reference point, the minimum distinguishable difference increases to 0.106 mIU/L (or a range of 0.347-0.453 mIU/L). However, we make the point that "accident" (error) rate is also an important consideration in a duplicates vs singletons decision [see Raggatt (5)].
In Figure 4 , the between-assay discrimination characteristics have been replotted in terms of D(%). In general, clinicians may find it easier to visualize performance characteristics, or to express performance re- quirements, in terms of minimum distinguishable percentage differences; e.g.: "Ideally, I would like this assay to distinguish concentration differences that do not exceed 15% (±7.5%), with P <0.01."
Clinical Working Range
Limits of the "working range" or "quantitative measurement range" (7) are generally defined by convenient round numbers (e.g., CV = 10%, or CV = 15% in the case of iinmunoassays).
Diagrams such as Figures  3 and 4 help clinicians directly define the concentration range within which the performance of a particular assay satisfies their perceived requirements. Different discrimination criteria can be freely used at the highand low-concentration regions, according to clinical relevance.
If the variance function method used here (or a similar one) is not available, a simple manual approach might suffice. Between-assay reproducibility data (e.g., Figure 28 ) are plotted in terms of CV and a flexi-rule is used to approximate the between-assay imprecision profile. Figure 5 (easily reproduced on graph paper) illustrates the general relationship between D(%) and CV. Thus, if a clinician regards quantitative measurement, for a particular assay and clinical context, as distinguishing concentration differences that do not exceed 20% (±10%), with P <0.05, then the critical between-assay CV is -8.6%. Reference to the betweenassay imprecision proffle establishes the effective clinical working range. Figure 5 can also be used in reverse, to quickly convert a particular CV value to a clinicianoriented measure (with stated significance level).
Least Detectable Concentration
Commonly, a small within-assay experiment is used to measure variability at zero concentration, and then the assay sensitivity (detection limit) is defined as the concentration two or three standard deviations from zero (effectively a confidence interval about zero, analogous to Figure IA) . Values obtained by this approach are easily misinterpreted as the minimum concentration distinguishable from zero and generally give a falsely optimistic picture. In contrast, the method used here (analogous to Figure 18 ) evaluates the minimum concentration at which results from a specimen can be considered statistically different from results that would be generated if the assay zero calibrator were assayed repeatedly as a clinical specimen (either within an assay or in a series of consecutive assays). McConway et al. (8) used a similar method. The main assumption, that variability is constant in the region of the LDC, is an assumption we find well justified, in that variance functions are consistently almost horizontal in the region near zero (e.g., Figure 2A, B) . This approach has the additional advantage that it can utilize large quantities of data collected under routine clinical conditions and can therefore provide estimates of the variability that are both statistically reliable and realistic.
In the within-assay mode and for duplicate measurement, the estimated LDC values for our TSH IRMA were 0.051 (P <0.05) or 0.073 mIUIL (P <0.01). Corresponding estimates for singleton measurement were 0.073 (P <0.05) or 0.104 mIU/L (P <0.01). In the between-assay mode, the estimates for duplicate measurement were 0.069 (P <0.05) or 0.099 mIU/L (P <0.01); those for singleton measurement were 0.086 (P <0.05) or 0.126 mIU/L (P <0.01). The between-assay estimates are the minimum concentrations that can be considered statistically distinguishable from zero over a series of representative assay batches.
Bayer (7) has pointed out that the LDC lies well below the region of quantitative measurement and in this sense has limited diagnostic relevance. The LDC may nevertheless be helpful in somesituations, e.g., to assess whether a drug measurement can be considered "real" or within the noise region of the assay. Between-assay LDC is the appropriate reference quantity in a clinical context.
DiscussIon
The trend to market-driven health care raises important issues regarding the best use of resources, issues that were somewhat less urgent in times of more plentiful funding. In the laboratory context, some relevant questions include the following Is this assay delivering the performance that (local) clinicians require? Are some of our assays delivering better discriminatory power than is actually needed? Can we improve the overall clinical value of our results (particularly within groups of diagnostically related tests) by reallocating resources? Any serious attempt to answer these questions requires detailed advice or comment from senior clinicians.
Our experience suggests that clinicians find the quantities D or D(%) not only easily comprehensible but also preferable to the CV scale. In addition, plots such as Figures 3 and 4 appear to have given our laboratory staff a better appreciation of the analytical limitations of assays, particularly, the limitations as they would be perceived by a "consumer." However, D or D(%) is just one possible representation. If a particular clinician can describe a more readily interpretable measure, it should, in principle, be easily derived from estimates of reproducibility.
Between-assay variability, the main determinant of clinical utility, consists of within-assay variability plus a between-assay component of variability. Thus, any strategy that improves within-assay reproducibility (including increased replication) will improve clinical utility. Use of additional replicates may not be obvious for laboratory organization or cost reasons, but is worth consideration as a temporary measure, e.g., if a particular subgroup of specimens can be identified as more "crucial" than average. The cost involved is easily calculated; the gain can be predicted via equation 3. The between-assay component of variability is determined (in a robust assay) by the reliability of calibration. Thus, the stability of assay calibration samples and the number of calibration samples and (or) replicates included in each assay batch are the obvious factors. A possibly underrated factor is the computer program used to estimate the calibration relationship: for example, several methods have been proposed for calculating results of immunoassays, but they are not necessarily equally reliable (see, e.g., 9-13).
Staff reductions and other cost pressures have recently forced us to switch to singleton TSH measurement in this laboratory (evaluation of >3000 duplicate results had previously shown an acceptably low error rate). A consulting physician who studied Figures 3  and 4 concluded that the assay was entirely satisfactory in the mid-euthyroid to hypothyroid range (duplicate or singleton measurement). However, near the lower reference point, and taking into account specialist clinical requirements, the assay was considered barely adequate when performed with duplicate measurement and obviously less so with singletons. As a short-term compromise, we have increased the replication of the three lowest-concentration calibrators (0.15, 0.5, and 1.5 mIU/L) from duplicate to quadruplicate (the zero calibrator is routinely used in quadruplicate). "Black box" methodologies, although undoubtedly labor saving, greatly restrict options, in the sense that calibration and other characteristics of (potentially) many assays are entirely in the hands of a remote third party. A case could be made for well-informed local clinical input, before deciding on one instrument vs another. Clinician involvement may become especially relevant if automation is accompanied by a drift to the use of less-skilled laboratory staff.
We concludewith two notes of caution. First, as Ekins (1) pointed out, in the most common diagnostic setting the reliability that a clinician can place on a measurement is determined by the variability that would be observed if clinical specimens from different subjects, containing an identical concentration of test analyte, were each assayed in a different batch. These data are almost impossible to obtain, and in practice we are restricted to assaying the same specimen (i.e., a QC specimen) in different batches. Resulting estimates of between-assay variability (Figure 28, C) and translations of them (e.g., Figures 3 and 4) should therefore be regarded as the best that can be expected from an assay.
Second, misleading estimates can easily result from inadequate attention to the data: either too few data, or data that do not reflect routine clinical conditions. Because of unusual circumstances, the 9-month datacollection period used here was considerably longer than would ordinarily have been necessary. In fact, before analysis we first subdivided the data by 6-week periods and by technician to check that no systematic trends or differences existed. No hard and fast rules can be stated regarding the minimum quantity of data needed. Given our experience with 95% confidenceintervals, we would feel uncomfortable estimating within-assay variability with <400 duplicates, or estimating between-assay variability with <150 QC specimen results. We use a normal deviate (Z) rather than a Student's t deviate in equations 5 and 7 as a reminder of these considerations. The main computer program (6) used in the analysis conferred obvious advantages such as convenience, reliability, and a prediction facility. However, if suitable between-assay reproducibility data are available, some reasonable approximations can be obtained with two sheets of graph paper and a flexi-rule.
Appendix: Predicting Between-Assay VarIabIlIty
If a QC specimen is measured with r0 replicates in each of several assay batches, the expected variance of the means (i.e., means of re replicates) is given by the standard expression (see, e.g., 15): We tested it numerically by using odd/ even pseudorandom digits to randomly select one of the two duplicates that were available for each of the 186 QC results, then estimated the between-assay variance function from these genuine singleton results. We repeated the process 20 times, using a different sequence of pseudorandom digits on each occasion. The mean of the 20 estimated variance functions was virtually superimposable on the prediction obtained via equation 4.
